Related Experiment Video
Updated: Nov 14, 2025

Author Spotlight: Point-of-Care Ultrasound for Gastric Content Assessment and Risk Stratification in Perioperative Care
Published on: September 22, 2023
[Stress ulcer prophylaxis for critically ill children: Routine use needs to be re-examined]
Sohair Sayed Abu El-Ella1, Muhammad Said El-Mekkawy1, Ali Mohamed Selim1
1Departamento de Pediatría, Facultad de Medicina, Universidad de Menufia, Shibin el-Kom, Egipto.
Insights
Stress ulcer prophylaxis (SUP) with omeprazole did not prevent gastrointestinal bleeding in critically ill children. This practice, however, increased the risk of central line-associated bloodstream infections (CLABSI), suggesting restricted use in pediatric intensive care units (PICUs).
Area of Science:
- Pediatric critical care medicine
- Pharmacology
- Gastroenterology
Context:
- Stress ulcer prophylaxis (SUP) is frequently administered in Pediatric Intensive Care Units (PICUs).
- Limited high-quality evidence supports routine SUP in pediatric populations.
- There is a need for randomized controlled trials (RCTs) to guide SUP practices in critically ill children.
Purpose:
- To evaluate the efficacy of omeprazole for stress ulcer prophylaxis in critically ill children.
- To assess the impact of omeprazole on upper gastrointestinal bleeding and nosocomial infections.
- To determine the safety and effectiveness of SUP in a pediatric intensive care setting.
Summary:
- A randomized controlled trial involving 144 pediatric patients with mild to moderate organ dysfunction (pSOFA < 16) compared omeprazole SUP to no SUP.
- No significant difference in gastrointestinal bleeding or ventilator-associated pneumonia (VAP) was observed between groups.
- The omeprazole group showed a significantly higher incidence of central line-associated bloodstream infections (CLABSI) (30.6% vs. 12.5%, p=0.014).
- Mechanical ventilation was identified as an independent predictor of bleeding (OR 6.4).
Impact:
- Omeprazole SUP is not effective in preventing gastrointestinal bleeding in non-ventilated PICU patients with mild to moderate organ dysfunction.
- Routine SUP with omeprazole in this population increases the risk of CLABSI.
- Findings support restricting SUP to mechanically ventilated children in the PICU setting.
Introduction:
Stress ulcer prophylaxis (SUP) is commonly used in Paediatric Intensive Care Units (PICUs). However, strong evidence for this practice is lacking and there is a dire need for paediatric randomized controlled trials (RCTs). Our aim was to assess the usefulness of SUP with omeprazole in critically ill children.
Patients And Methods:
We conducted a randomized, controlled open-label trial, including 144 children admitted into a PICU with a paediatric Sequential Organ Failure Assessment (pSOFA) score of less than 16. We randomly allocated patients to SUP with omeprazole or no SUP. The primary outcome was development of upper gastrointestinal bleeding or nosocomial infection.
Results:
The incidence of gastrointestinal bleeding was 27.1%, but clinically significant bleeding developed in only 5.6% of patients. We did not find a significant difference in the incidence of bleeding between the prophylaxis and control groups (27.8 vs. 26.4%; p = 0.85). We also did not find a significant difference between the group in the incidence of ventilator-associated pneumonia (VAP) (9.6 vs. 8.3%; p = 0.77). The incidence of central line-associated bloodstream infection (CLABSI) was higher in the prophylaxis group compared to the control group (30.6% vs. 12.5%; p = 0.014). None of the patients developed Clostridium difficile-associated diarrhoea. We did not find significant differences in mortality, length of PICU stay or duration of mechanical ventilation. Mechanical ventilation was an independent predictor of bleeding (OR 6.4; 95% CI, 2.73-14.9).
Conclusion:
In PICU patients with mild to moderate organ dysfunction, omeprazole does not seem to be useful for prevention of gastrointestinal bleeding while at the same time increasing the risk of CLABSI. Thus, we recommend restricting SUP to mechanically ventilated children.
Related Concept Videos
Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
Peptic Ulcer Disease V: Surgical Management and Nursing Care
Surgical Interventions for Peptic Ulcer Disease
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...

